Caxton Associates (New York)’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $440K | Sell |
206,380
-35,722
| -15% | -$76.1K | 0.01% | 356 |
|
|
2024
Q3 | $678K | Sell |
242,102
-224,008
| -48% | -$627K | 0.03% | 314 |
|
|
2024
Q2 | $1.09M | Buy |
466,110
+34,924
| +8% | +$81.4K | 0.04% | 235 |
|
|
2024
Q1 | $1.93M | Sell |
431,186
-343,907
| -44% | -$1.54M | 0.11% | 127 |
|
|
2023
Q4 | $2.49M | Buy |
775,093
+294,989
| +61% | +$947K | 0.13% | 95 |
|
|
2023
Q3 | $1.52M | Buy |
480,104
+410,520
| +590% | +$1.3M | 0.21% | 80 |
|
|
2023
Q2 | $346K | Buy |
69,584
+47,756
| +219% | +$237K | 0.05% | 320 |
|
|
2023
Q1 | $108K | Buy |
+21,828
| New | +$108K | 0.02% | 458 |
|
|
2022
Q2 | – | Sell |
-41,645
| Closed | -$379K | – | 535 |
|
|
2022
Q1 | $379K | Buy |
+41,645
| New | +$379K | 0.03% | 293 |
|